New aspects in thrombotic research: Complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype

被引:47
作者
Wojta, J
Huber, K
Valent, P
机构
[1] Med Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria
[3] Wilheminenspital, Med Deot Cardiol & Emergency Med 3, Vienna, Austria
关键词
mast cells; thrombosis; complement; plasminogen activation;
D O I
10.1159/000083842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mast cells, strategically located in the vicinity of blood vessels, are multifunctional effector cells participating in the modulation of various inflammatory and cardiovascular disease processes by actively releasing a wide variety of vasoactive mediators. These cells have also been implicated in the regulation of thrombosis and the development and progression of atherosclerosis. By expressing enzymatically active tissue type-plasminogen activator (t-PA), human mast cells (MC) might play a role in endogenous fibrinolysis and extra cellular matrix remodelling - both processes that are essential in the pathogenesis of cardiovascular disorders. However, when treated with the anaphylotoxin C5a, mast cells express the PA inhibitor 1 (PAI-1) in excess over t-PA. In context with studies suggesting a role for mast cells and components of the complement system in the development of cardiovascular disease our results lead to the hypothesis that mast cells by producing t-PA in a resting state and by expressing PAI-1 when activated by C5a might participate in the modulation of the balance between proteases and protease inhibitors regulating tissue injury and repair in these disease processes. In addition, C5a might upregulate PAI-1 in mast cells to prevent its own inactivation by plasmin in an autocrine or paracrine fashion. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:438 / 441
页数:4
相关论文
共 25 条
[1]   INCREASE AND REDISTRIBUTION OF CARDIAC MAST-CELLS IN AURICULAR THROMBOSIS - POSSIBLE ROLE OF KIT-LIGAND [J].
BANKL, HC ;
RADASZKIEWICZ, T ;
KLAPPACHER, GW ;
GLOGAR, D ;
SPERR, WR ;
GROSSSCHMIDT, K ;
BANKL, H ;
LECHNER, K ;
VALENT, P .
CIRCULATION, 1995, 91 (02) :275-283
[2]   Human mast cells release metalloproteinase-9 on contact with activated T cells:: Juxtacrine regulation by TNF-α [J].
Baram, D ;
Vaday, GG ;
Salamon, P ;
Drucker, I ;
Hershkoviz, R ;
Mekori, YA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (07) :4008-4016
[3]   Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma [J].
Cho, SH ;
Tam, SW ;
Demissie-Sanders, S ;
Filler, SA ;
Oh, CK .
JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :3154-3161
[4]  
Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1
[5]   COMPLEMENT PEPTIDES C3A-INDUCED AND C5A-INDUCED MEDIATOR RELEASE FROM DISSOCIATED HUMAN SKIN MAST-CELLS [J].
ELLATI, SG ;
DAHINDEN, CA ;
CHURCH, MK .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (05) :803-806
[6]  
Fang KC, 1999, J IMMUNOL, V162, P5528
[7]   Mast cells and basophils [J].
Galli, SJ .
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (01) :32-39
[8]   Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial [J].
Granger, CB ;
Mahaffey, KW ;
Weaver, WD ;
Theroux, P ;
Hochman, JS ;
Filloon, TG ;
Rollins, S ;
Todaro, TG ;
Nicolau, JC ;
Ruzyllo, W ;
Armstrong, PW .
CIRCULATION, 2003, 108 (10) :1184-1190
[9]   C3a and C5a stimulate chemotaxis of human mast cells [J].
Hartmann, K ;
Henz, BM ;
KrugerKrasagakes, S ;
Kohl, J ;
Burger, R ;
Guhl, S ;
Haase, I ;
Lippert, U ;
Zuberbier, T .
BLOOD, 1997, 89 (08) :2863-2870
[10]  
HIGAZI AAR, 1994, J BIOL CHEM, V269, P25529